Team Led by Dr. Rohit Mehra discovers New Diagnostic Biomarker for Kidney Cancer

By Elizabeth Walker | October 11 2018

VSTM2A expression in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney.A recent collaborative study out of the Michigan Center for Translational Pathology (MCTP) has led to new insight into kidney cancer. The resulting paper, VSTM2A Overexpression is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney, is published in the American Journal of Surgical Pathology (AJSP).

The team from the Department of Pathology and MCTP, led by Dr. Rohit Mehra, joined colleagues from the Michigan Medicine Department of Urology, Rogel Cancer Center, and the Howard Hughes Medical Institute in Ann Arbor and others from Memorial Sloan Kettering Cancer Center, Rutgers Cancer Institute, Johns Hopkins Medical Institutions, The University of Texas Southwestern Medical Center, El Camino Hospital, University of Calgary, Emory University, Vanderbilt University School of Medicine, and the Cleveland Clinic for this project.

The team’s work revealed that there are recurrent chromosomal losses and somatic mutations of genes in the Hippo pathway in MTSCC and to the discovery of a new diagnostic biomarker.

Read the full paper at the AJSP.

Rate this Article: